Table 2 Comparison of this assessment to baseline studies: only presenting cancers cases (except testicle)
Type of cancer (number of Deaf cases) | Stage | % observed in the sample studied (nomber) | % of the reference population | Baseline studies |
|---|---|---|---|---|
Colo-rectal (n = 6) | I | – | 25.7% | PETRI (Fr) [24] (37,413 patients) |
II | – | 21.3% | ||
III | 67% (4) | 20.6% | ||
IV | 33% (2) | 26.5% | ||
NDa | – | 5.9% | ||
Melanoma (n = 3) | I and II | – | 86.2% | PETRI (Fr) [24] (7401 patients) |
III | 33% (1) | 3.4% | ||
IV | 67% (2) | 6.4% | ||
NDa | – | 4% | ||
Hodgkin’s lymphoma (n = 3) | I | – | 81.7% | PETRI (Fr) [24] (1544 patients) |
II | – | 8.7% | ||
III | 67% (2) | 3.8% | ||
IV | – | 3.8% | ||
NDa | 33% (1) | 2.0% | ||
Non-Hodgkin’s lymphoma (n = 4) | Localized | 25% (1) | 30% | SEER (USA) [25] (10,224 patients) |
Regional | 50% (2) | 15% | ||
Metastatic | 25% (1) | 47% | ||
NDa | – | 9% | ||
Lung (n = 3) | I | – | 15.5% | PETRI (Fr) [24] (31,557 patients) |
II | 33% (1) | 13.6% | ||
III | – | 20% | ||
IV | 67% (2) | 39.4% | ||
NDa | – | 11.5% | ||
Prostate (n = 11) | T1N0M0 | 9% (1) | 27.4% | « Cancer de la prostate en France en 2001 » [21] (2181 patients) |
T2N0M0 | 9% (1) | 59.2% | ||
T3/T4N0M0 | 46% (5) | 3.0% | ||
N + M+ | 18% (2) | 10.4% | ||
NDa | 18% (2) | – | ||
Breast (n = 15) | T1 | 33% (5) | 66% | Breast cancer incidence: Decreasing trend in large tumours in women aged 50–74 [22] (28,092 patients) |
T2+ | 60% (9) | 34% | ||
NDa | 7% (1) | – | ||
N0 | 53% (8) | 63% | ||
N+ | 40% (6) | 33% | ||
NDa | 7% (1) | 4% | ||
M0 | 93% (14) | 90.5% | ||
M+ | 1 (7%) | 4.5% | ||
NDa | – | 5% | ||
Thyroid (n = 3) | I | 67% (2) | 67.9% | PETRI (Fr) [24] (6672 patients) |
II | 33% (1) | 6.4% | ||
III | – | 9.2% | ||
IV | – | 9.2% | ||
NDa | – | 7.3% | ||
Uterine (n = 3) | Localized | 67% (2) | 69% | SEER (USA) [25] (5774 patients) |
Regional | – | 19% | ||
Metastatic | 33% (1) | 8% | ||
NDa | – | 4% |